TMF/ARA160 is a Golgi resident protein whose cellular functions have not been conclusively revealed. Herein we show that TMF/ARA160 can direct the proteasomal degradation of the key cell growth regulator -Stat3. TMF/ARA160 was dispersed in the cytoplasm of myogenic C2C12 cells that were grown under low-serum conditions. The cytoplasmic distribution of TMF/ARA160 was accompanied by its transient association with the tyrosine kinase Fer and with Stat3, which underwent proteasomal degradation under those conditions. Moreover, serum deprivation induced the association of ubiquitinated proteins, with the TMF/ARA160 complex. However, TMF/ ARA160 did not bind Stat1, whose cellular levels were increased in serum-starved C2C12 cells. Amino-acid sequence analysis identified a BC-box element in TMF/ ARA160 that mediated the binding of this protein to elongin C. Ectopic expression of TMF/ARA160 in serumstarved C2C12 cells drove the ubiquitination and proteasomal degradation of Stat3, an effect that was not caused by TMF/ARA160 devoid of the BC-box motif. Thus, the Golgi apparatus harbors a novel BC-box-containing protein that can direct Stat3 to proteasomal degradation. Interestingly, the level of TMF/ARA160 was significantly decreased in malignant brain tumors, implying a suppressive role of that protein in tumor progression.
Introduction
TMF/ARA160 is a Golgi resident protein (Mori and Kato, 2002) which consists of 1093 amino acids with an apparent molecular mass of 160 kDa (Hsiao and Chang, 1999) . This protein was initially identified as a DNAbinding factor that preferentially binds to the TATA element in the human immunodeficiency virus 1 (HIV1) long-terminal repeat (LTR) and modulates its functioning (Garcia et al., 1992) . It was therefore termed 'TATA Element Modulatory Factor' (TMF) (Garcia et al., 1992) . TMF was later characterized as a potential coactivator of the androgen receptor (AR), thus endowing it the name AR-coactivator 160 kDa (ARA160) (Hsiao and Chang, 1999) . The central and C-terminal parts of TMF/ARA160 contain coiled-coil (cc) forming domains that could mediate the interaction of that protein with other cellular factors. Several cellular proteins besides nuclear receptors were found to interact with TMF/ARA160, in various proteinprotein binding assays. These include the Rab6 GTPbinding protein that seems to anchor TMF/ARA160 to Golgi membranes (Fridmann-Sirkis et al., 2004) , ATPase subunits of the human chromatin remodeling complex SNF/SWI-hbrm/hSNF2a and BRG-1/hSNF2b (Mori and Kato, 2002) and the intracellular tyrosine kinase Fer (Schwartz et al., 1998) . Interestingly, the Rab6-, AR-and Fer-binding domains in TMF/ARA160 overlap, and include cc forming sequences (Schwartz et al., 1998; Hsiao and Chang, 1999) . However, the above-described findings did not conclusively reveal the function of TMF/ARA160 in vivo, and its cellular role remained elusive. We therefore sought to further explore a functional link between TMF/ARA160 and the intracellular tyrosine kinase Fer.
Fer (p94 fer ) is an evolutionarily conserved (Pawson et al., 1989; Paulson et al., 1997) and ubiquitously expressed tyrosine kinase that resides in the cytoplasm and nucleus of mammalian cells (Letwin et al., 1988; Hao et al., 1989 Hao et al., , 1991 Kim and Wong, 1998; Ben-Dor et al., 1999) . In the cytoplasm, Fer associates with and phosphorylates cell adhesion molecules like cortactin and b-catenin (Kim and Wong, 1998; Rosato et al., 1998; Piedra et al., 2003) and its kinase activity increases in growth factor-stimulated cells (Kim and Wong, 1995) . Fer associates also with the signal transducer and activator of transcription 3 (Stat3), and it can lead to the tyrosine phosphorylation and activation of this transcription regulatory factor Orlovsky et al., 2002) .
Stat3 is a key regulator of both cell growth and differentiation (Hauser et al., 1998; Bromberg et al., 1999) , whose activation is induced by several extracellular stimuli. It is activated in cells treated with IL-6 and its cytokine family members (Ihle, 2001) . Noncytokine ligands such as EGF, PDGF, HGF and leptins were also shown to elicit the phosphorylation and activation of Stat3 (Bromberg and Chen, 2001) . The involvement of Stat3 as a positive regulator of cell growth is manifested by its potential oncogenic activity (Bromberg et al., 1999) and its constitutive activation in a great variety of human tumors . Constitutive activation of Stat3 was found to be essential for cellular transformation by v-src and several other oncogenic tyrosine kinases, including v-Abl, vFps, Bcr-Abl and v-Eyk . Stat3 exerts its oncogenic activity by inducing both cell-cyclepromoting and antiapoptotic genes (Bromberg et al., 1999) .
Several modulators of the Stat3 activation pathways have been characterized. These include proteins which downregulate upstream activators of Stat3 (Croker et al., 2003; Lang et al., 2003) or proteins that directly bind Stat3 and impair its transcription-activating function (Lufei et al., 2003) .
Together, these findings suggest that Stat3 and its putative activator Fer are involved in the regulation of cell growth and in cellular transformation. In accordance with that conclusion, it was found that, while the function of Fer is redundant in the normal mouse, and mice devoid of a functional Fer are viable and fertile (Craig et al., 2001) , this tyrosine kinase is highly expressed in prostate tumors and it is essential for the proliferation of malignant cell lines (Allard et al., 2000; Orlovsky et al., 2000) .
To reveal whether TMF/ARA160 regulates the growth-controlling activities of Fer and/or Stat3, the subcellular distribution and mutual interaction of these proteins were analysed in actively growing and growtharrested cells. C2C12 myoblasts that can undergo growth arrest and a consequent myogenic differentiation in culture (Walsh and Perlman, 1997; Kronfeld-Kinar et al., 1999) were used in the current study. In these cells, the Golgi undergoes re-organization and cytoplasmic dispersion upon transition to a growth arrest state (Lu et al., 2001) . This system enabled us to demonstrate a novel regulatory link between TMF/ARA160 and Stat3. TMF/ARA160 was found to recruit Stat3 to proteasomal degradation, a role that portrays this Golgi resident protein as a novel modulator of cell growth. Supporting this notion, we showed that the level of TMF/ARA160 is significantly decreased in malignant brain tumors.
Results
TMF/ARA160 is dispersed in the cytoplasm of serum-deprived C2C12 cells TMF/ARA160 has been implicated previously as a regulator of genes transcribed by RNA polymerase II (RNA POL.II) (Garcia et al., 1992; Hsiao and Chang, 1999) . However, the accumulation of TMF/ARA160 in the Golgi implies its restricted accessibility to nuclear or cytoplasmic proteins like the AR or the growthcontrolling tyrosine kinase Fer. We therefore examined the subcellular distribution of TMF/ARA160, in actively growing and growth-arrested cells. Myogenic C2C12 cells were grown under normal growth conditions and were then transferred to low-serum conditions, under which they underwent gradual differentiation and terminal growth arrest (Walsh and Perlman, 1997; Kronfeld-Kinar et al., 1999) . Cells were subjected to immunocytochemical analysis, before and after being transferred to 0.5% FCS, for 48 h. While residing in the Golgi of actively growing cells (Figure 1a ), TMF/ ARA160 was partially dispersed in the cytoplasm of cells that were grown for 24 h under low-serum growth conditions (data not shown). TMF/ARA160 was almost fully spread throughout the cytoplasm, after 48 h of lowserum growth conditions (Figure 1b ). This profile reflected the redistribution of the Golgi apparatus in C2C12 myoblasts that undergo growth arrest under lowserum growth conditions (Figure 1c and d; Lu et al., 2001) .
TMF/ARA160 associates with Fer and Stat3 in serum-deprived C2C12 cells
The redistribution of TMF/ARA160 in serum-starved cells could increase the accessibility of TMF/ARA160 to defined cytoplasmic components. One candidate protein that might interact with TMF/ARA160 in the cytoplasm is the tyrosine kinase Fer that was shown to bind to TMF/ARA160, in a yeast two-hybrid screening system (Schwartz et al., 1998) . This kinase is mainly cytoplasmic in both actively growing and serum-starved C2C12 cells (data not shown).
Western blot analysis of whole-cell extracts revealed that, while the level of TMF/ARA160 remained similar ( Figure 2a, lanes 1-4) , the level of Fer declined significantly during the starvation process of the C2C12 cells (Figure 2a, lanes 1-4) . The decrease in the Fer level was abolished in cells treated with the proteasome inhibitor MG132 (Figure 2a , lanes 5-8), suggesting that Fer is prone to proteasomal degradation under those conditions. Interestingly, the level of TMF/ ARA160 was also increased in MG132-treated cells (Figure 2a, , indicating the subjection of TMF/ARA160 as well to proteasomal degradation under those conditions.
To test the possible association of these two proteins, TMF/ARA160 was immunoprecipitated from nonstarved and from serum-deprived C2C12 cells by using affinity-purified anti-TMF/ARA160 antibodies. Wholecell extracts were prepared from actively growing C2C12 cultures and from cells grown with 0.1% serum, for 24, 48 and 72 h. Anti-TMF/ARA160 immunoprecipitates were resolved by SDS-PAGE and were then subjected to anti-TMF/ARA160 and anti-Fer antibodies in a Western blot analysis. TMF/ARA160 was immunoprecipitated from the different extracts with similar TMF/ARA160 mediates degradation of Stat3 E Perry et al efficiency (Figure 2b ). However, significant levels of coimmunoprecipitated Fer were detected only after 24 and 48 h of serum starvation (Figure 2b, lanes 1-4) . Thus, the Fer kinase transiently associates with TMF/ ARA160, in serum-starved C2C12 cells.
Exposing the TMF/ARA160 immunoprecipitates to antiphosphotyrosine antibodies (aPY) did not reveal a 94 kDa protein (data not shown), indicating that the Fer fraction associated with TMF/ARA160 is not phosphorylated on tyrosine.
Since Fer seemed to be subjected to proteasomal degradation in serum-starved C2C12 cells, immunoprecipitations were performed also from extracts of cells that were exposed to the proteasome inhibitor MG132. Fer associated transiently with TMF/ARA160 in these treated cells as well. However, the levels of Fer associated with TMF/ARA160 increased significantly in cells that were treated with MG132, and became maximal after 24 h of serum starvation (Figure 2b , lanes 6 and 7).
The Fer kinase was shown previously to associate with Stat3 in C2C12 and in NIH3T3 cells (PrielHalachmi et al., 2000) . This raised the possibility that Stat3 also associates with the TMF/ARA160-Fer To examine whether Stat3 associates with TMF/ ARA160, proteins precipitated with anti-TMF/ARA160 antibodies were resolved in SDS-PAGE and were then reacted with anti-Stat3 antibodies, in a Western blot analysis. As was seen for the tyrosine kinase Fer (Figure 2b ), Stat3 did not associate with TMF/ ARA160 in actively growing, nonstarved cells ( Figure 3b, lanes 1 and 5) . However, after 24 and 48 h of serum starvation, Stat3 associated with TMF/ ARA160 and this association was barely seen after 72 h of serum starvation (Figure 3b, lanes 1-4) . The transient association of these two proteins increased significantly in cells treated with MG132, and was maximal after 24 h of serum starvation (Figure 3b , lanes 5-8).
To assess the specificity of the interaction between TMF/ARA160 and Stat3, the association of TMF/ ARA160 with Stat1 was analysed as well. Unlike Stat3, which in many systems is implied in promoting cell proliferation (Bromberg et al., 1999; Sinibaldi et al., 2000) , Stat1 is linked mainly to impaired cell growth (Zhou et al., 2001) . In agreement with this notion, the cellular levels of Stat1 increased gradually in serumdeprived C2C12 cells ( Figure 3a , lanes 1-8). Exposing the TMF/ARA160 immunoprecipitates to anti-Stat1 antibodies in a Western blot analysis did not reveal any association of Stat1 with TMF/ARA160 in proliferating or in serum-starved cells ( Figure 3b , lanes 1-8). This proved the specificity of the interaction between TMF/ ARA160 and Stat3 or Fer, which are linked to the proliferation of mammalian cells.
TMF/ARA160 associates with ubiquitinated proteins in serum-starved C2C12 cells
The augmented association of TMF/ARA160 with proteasome degradable Stat3 implied the involvement of TMF/ARA160 in the recruitment of Stat3 to proteasomal degradation. To confirm the direct link of TMF/ARA160 to ubiquitin-dependent protein degradation, the association of ubiquitinated proteins with TMF/ARA160 was examined. TMF/ARA160 was immunoprecipitated from both actively growing and from serum-starved C2C12 cells that were also exposed to the proteasome inhibitor MG132, and the precipitated proteins were resolved by SDS-PAGE. Western TMF/ARA 160 harbors a BC-box and binds elongin C The association of TMF/ARA160 with proteasome degradable Stat3 and ubiquitin complexes suggested the involvement of TMF/ARA160 in the regulated degradation of Stat3. To get a better understanding of the functional role of TMF/ARA160 in the proteasomal degradation of Stat3, a search for E3 ubiquitin ligase motifs in the protein was performed. Computerized analysis did not identify F-box motifs that are commonly found in some adaptor component of E3 ubiquitin ligase (Craig and Tyers, 1999; Jackson and Eldridge, 2002) . However, manual inspection revealed the existence of a BC-box which extends from Ser-333 to Ile-342 (Garcia et al., 1992; Conaway et al., 1998; Kamura et al., 1998) in the N-terminal tail of TMF/ ARA 160 (Figure 5a and b) . BC-box mediates the binding of several proteins like the transcription elongation factor elongin A, the E3 ubiquitin ligase adaptor VHL and suppressors of cytokine signaling (SOCS) proteins, to elongin C Kamura et al., 1998) . Hence, binding to elongin C could recruit a protein to a variety of regulatory complexes, among them also an E3 ubiquitin ligase complex .
To test the functional relevance of the identified BCbox in TMF/ARA160, the binding of elongin C to that element was analysed. HA (Hemagglutinin) tagged TMF/ARA160 (HA-TMF), TMF/ARA160 deleted of the BC-box element (HA-DBCTMF) and TMF/ ARA160 devoid of its C-terminal cc forming sequences (NterTMF/ARA160) ( Figure 5a ) were each co-transfected together with a myc-tagged elongin C to C2C12 cells (Figure 5c ), and the HA-TMF/ARA160 variants were immunoprecipitated with anti-HA antibodies. Precipitated proteins were resolved in SDS-PAGE and the co-precipitation of myc-elongin C was tested using anti-myc antibodies in a Western blot analysis. While intact TMF/ARA160 and TMF devoid of the Cterminal cc sequences bound and efficiently precipitated elongin C, TMF/ARA160 deleted of the BC-box led to the co-precipitation of only marginal level of mycelongin C (Figure 5d ). Thus, TMF/ARA160 can associate with elongin C and the BC-box plays a key role in this association.
TMF/ARA160 directs the ubiquitination and proteasomal degradation of Stat3 in serum-deprived C2C12 cells
To directly examine the involvement of TMF/ARA160 in the ubiquitination of Stat3 in vivo, serum-starved C2C12 cells were co-transfected with a His 6 -Stat3 plasmid and either with a plasmid encoding intact TMF/ARA160 (HA-TMF) or with a plasmid encoding a BC-box-deleted TMF/ARA160 (HA-DBCTMF), or with the empty vector alone (pCDNA3). Whole-cell proteins were extracted with a guanidinium-HCl buffer and His 6 -Stat3 was then purified on a Co 2 þ -agarose column. The usage of a denaturing lysis buffer ensured the dissociation of any noncovalently attached molecules from the purified His 6 -Stat3 (Treier et al., 1994) . Proteins eluted from the Co 2 þ -Sepharose column were resolved in SDS-PAGE and were then reacted with antiubiquitin and anti-Stat3, in a Western blot analysis. Coexpression with HA-TMF led to the ubiquitination of His6-Stat3 and accumulation of high molecular weight LD-AAA), and this modified TMF/ ARA160 protein was termed HA-ATMF. These three residues were found to be required for the functioning of the elongin C-binding protein Vif of HIV-I (Yu et al., 2003) . Replacement of the three amino acids in TMF/ ARA160 strongly reduced the ubiquitination directing activity of the protein (Figure 6a, lane 3, and b, lane 3) , corroborating the presence of a functional BC-box in TMF/ARA160. To test the involvement of TMF/ ARA160 in the proteasomal degradation of Stat3, HA-TMF and HA-DBCTMF were transiently overexpressed in C2C12 cells, and their effects on the level of the endogenous Stat3 protein, were followed. Transient ectopic expression of HA-tagged TMF/ARA160 variants in cells grown under normal serum conditions resulted in their accumulation in the Golgi and in the cytoplasm, but did not lead to a change in the level of the endogenous Stat3 (data not shown). However, when the transfected cells were transferred for the last 24 h before harvest, to a growth medium containing 0.1% FCS, intact HA-TMF/ARA160 led to a marked decrease in the level of the endogenous Stat3 protein ( Kamura et al., 1998) , with the BC-box identified in TMF/ARA160. The aligned aa sequence extends from Ser-333 to Ile-342 in the human TMF/ARA160 (Garcia et al., 1992) . (c) C2C12 cells were co-transfected with an expression vector encoding a myc-tagged elongin C together with a pCDNA3 vector (lane 1), with a vector encoding TMF/ARA160 deleted of the BCbox, HA-DBCTMF (lane 2), with a vector encoding an intact HA-TMF/ARA160, HA-TMF (lane 3), or with a vector encoding the C-terminal truncated TMF/ARA160, HA-NterTMF (lane 4). Whole-cell lysates were prepared from all transfected cells, proteins were resolved in 8% SDS-PAGE and were then reacted with the corresponding antibodies in a Western blot analysis. (d) Proteins were immunoprecipitated from the prepared lysates using anti-HA antibodies. Precipitated proteins were resolved in 14% SDS-PAGE, and co-precipitation of myc-elongin C was detected using amyc antibodies in a Western blot analysis (lower panel). Precipitated HA-TMF/ARA160 variants were detected with anti-HA antibodies (upper panel) TMF/ARA160 mediates degradation of Stat3 E Perry et al
TMF/ARA160 is downregulated in malignant brain tumors
Stat3 is highly expressed and is constitutively activated in various human tumors (Magrassi et al., 1999; Bowman et al., 2000) . Since TMF/ARA160 is a novel regulator of Stat3, it could affect tumor progression and would therefore be downregulated in malignant tumors. To test this presumption, we analysed the levels of TMF/ARA160 in three types of brain tumors. These included the most malignant forms of the glioma brain tumors -the glioblastoma multiform (GBM) tumors (Dean et al., 1990) . In addition, two distinct meningioma subtypes were also analysed. These were benign meningioma tumors and their more aggressive form, the malignant anaplastic meningioma tumors (Lekanne Deprez et al., 1995) , which were shown to express relatively high levels of Stat3 (Magrassi et al., 1999; Rahaman et al., 2002 ).
Whole-cell protein extracts were prepared from the GBM samples and from the two meningioma subtypes, and the levels of TMF/ARA160 were determined using a Western blot analysis. The levels of TMF/ARA160 in the GBM samples were compared to the level of that protein in primary cells from rat cerebral cortex, of which more than 90% are glial cells (Williams and Herrup, 1988) . While the levels of the tyrosine kinase Fer were similar in both meningioma tumor groups, the level of TMF/ARA160 was significantly lower in malignant anaplastic meningiomas (Figure 8a ). Similarly, the level of TMF/ARA160 was profoundly reduced in GBM malignant tumors when compared to an enriched population of normal rat glial cells (Figure 8b) . Thus, the level of TMF/ARA160 is markedly decreased in aggressive, malignant brain tumors.
Discussion
TMF/ARA160 was originally characterized as a putative transcription factor and co-activator of nuclear receptors (Garcia et al., 1992; Hsiao and Chang, 1999) . The subcellular localization of TMF/ARA160 to the Golgi (Mori and Kato, 2002) , which is uncommon for a transcription factor, implies, however, additional functions of that protein. TMF/ARA160 was dispersed in the cytoplasm of growth-arrested C2C12 cells (Figure 1 ). This was accompanied by the distribution of other Golgi components, as revealed by staining with wheat germ agglutinin (WGA), and most probably reflects the 2) , with a vector encoding HA-DBCTMF (lanes 3 and 4), with a vector encoding HA-NterTMF (lane 5), or with a vector alone (lane 6). The cells were transferred to a medium containing 0.1% serum 24 h before harvest, and were either left untreated (À) or were exposed for the last 5 h to the proteasome inhibitor MG132. Proteins were extracted and resolved in 7% SDS-PAGE, and the levels of the endogenous Stat3 (upper panel), the ectopic HA-TMF/ARA160 (second panel), the endogenous Fer protein (third panel) and the endogenous actin protein (fourth panel) were determined using the corresponding antibodies, in a Western blot analysis TMF/ARA160 mediates degradation of Stat3 E Perry et al re-organization of the Golgi compartment, in growtharrested myogenic cells (Lu et al., 2001) . The restructuring of the Golgi in differentiating myoblasts (Lu et al., 2001) could therefore increase the accessibility of TMF/ARA160 to cytoplasmic proteins. Dispersion of TMF/ARA160 in the cytoplasm of C2C12 cells was accompanied by its association with two cytoplasmic proteins that were identified in the current work. These included the tyrosine kinase Fer and the key transcription regulator -Stat3. The association of Stat3 with TMF/ARA160 could be mediated by Fer, since Stat3 was previously shown to associate with Fer in vivo and Fer itself was found to directly interact with TMF/ ARA160, in a yeast two-hybrid screening system (Schwartz et al., 1998) . However, the association of Stat3 with TMF/ARA160 did not depend on the presence of Fer, since TMF/ARA160 also associated with Stat3 in the thymoma-derived T127 cells (Halachmy et al., 1997) , which lack the Fer kinase (data not shown). Thus, Stat3 and Fer bind independently to TMF/ARA160.
The levels of Stat3 and Fer dropped significantly in C2C12 cells after 72 h of serum starvation (Figures 3a  and 2a, lanes 1-4) . This downregulation was abolished in cells treated with the proteasome inhibitor MG132 (Figures 3a and 2a, lanes 5-8) , suggesting that Fer and Stat3 are prone to proteasomal degradation. Proteasomal downregulation of an inactive Fer (Craig et al., 2001 ) and of Stat3 (Daino et al., 2000) has been implicated before. Interestingly, both Fer and Stat3 were dephosphorylated on tyrosine and were both inactive, when they formed a complex with TMF/ ARA160 (data not shown).
The association of TMF/ARA160 with Fer and Stat3 was most prominent after 24 h of serum starvation, and increased significantly in cells treated with MG132 (Figures 2b and 3b) . This profile preceded but also overlapped the downregulation of Fer and Stat3, which was most apparent between 24 and 48 h of serum starvation. Thus, association with TMF/ARA160 could serve as an intermediate and preceding step in the degradation of Stat3 and Fer, under serum deprivation. This notion is supported by the fact that the TMF/ ARA160 complex contained ubiquitinated proteins already after 24 h of serum starvation (Figure 4, lanes  3-5) . Serum withdrawal for 24 h marked the onset of proliferation arrest in C2C12 cells, which was also manifested by the induced accumulation of Stat1 (Figure 3a , lower panel), which is linked to a cell growth arrest (Zhou et al., 2001) . It seems therefore that the association between TMF/ARA160 and Stat3 and Fer and the subsequent degradation of these proteins parallels the onset of proliferation arrest in C2C12 cells. In spite of the continuing decline in the levels of Stat3 and Fer after 72 h of low-serum conditions, these two proteins did not associate with TMF/ARA160 at that stage. This could be explained by the fact that most of the 72 h starved culture became fully differentiated and consisted mainly of differentiated myotubes (Taler et al., 2003) . The regulation of Stat3 level in terminally differentiated myotubes may therefore differ from its regulation in nondifferentiated cells.
The association of TMF/ARA160 with Stat3 and Fer is specific, since TMF/ARA160 did not associate with Stat1. Thus, TMF/ARA160 associates specifically with proliferation-promoting factors, and is involved in their downregulation.
Overexpression of TMF/ARA160 led to the ubiquitination and the subsequent proteasomal degradation of Stat3 in C2C12 cells (Figures 6 and 7) . These results directly demonstrate the involvement of TMF/ARA160 in the ubiquitination and proteasomal degradation of Stat3.
They also indicate that dispersion of TMF/ARA160 in the cytoplasm of C2C12 cells does not suffice for the recruitment of Stat3 to degradation, and TMF/ARA160 has to be activated under defined cellular conditions. C2C12 myoblasts undergo growth arrest and myogenic differentiation upon serum deprivation (Walsh and Perlman, 1997) . Further studies should therefore reveal whether the downregulation of a growth-promoting factor like Stat3 (Sinibaldi et al., 2000) by TMF/ ARA160 is an essential step in the growth arrest and subsequent differentiation of these cells. It should be noted that the level of Stat3 was also downregulated in C2C12 cells that were undergoing myogenic differentiation (Kronfeld-Kinar et al., 1999) under insulin treatment (data not shown).
While TMF/ARA160 bound Fer in serum-starved cells, ectopic overexpressed TMF/ARA160 did not affect the cellular level of that kinase (Figure 7 ). This could imply the necessity for another limiting factor that Whole-cell protein lysates were prepared from rat primary cortex cells (lanes 1 and 2) and from seven fresh GBM tumors (lanes 3-9). Proteins were resolved in SDS-PAGE and were then reacted with anti-TMF (upper panel), anti-Stat3 (middle panel) and anti-actin antibodies (lower panel), in a Western blot analysis TMF/ARA160 mediates degradation of Stat3 E Perry et al co-operates with TMF/ARA160 in recruiting Fer to degradation. Alternatively, it could be concluded that TMF/ARA160 acts specifically on Stat3 and is not directly involved in the degradation of Fer. In that case, the increased association of TMF/ARA160 and Fer in MG132-treated cells could reflect the increased level of Fer in these cells.
How does TMF/ARA160 direct the proteasomal degradation of Stat3? The association of TMF/ ARA160 with Stat3 and the presence of a BC-box in the N-terminus of TMF/ARA160 (Figure 5b ) suggest that this protein might be a part of an E3 ubiquitin ligase complex containing also the elongin B and C proteins . This notion is corroborated by the fact that, unlike the intact TMF/ ARA160, a TMF/ARA160 deleted of the BC-box element failed to direct the ubiquitination and proteasomal degradation of Stat3 (Figures 6 and 7) . Moreover, elongin C binds TMF/ARA160 through the BC-box element (Figure 5c ), and most probably recruits it to an E3 ubiquitin ligase complex, as was demonstrated for the VHL adaptor protein Kaelin Jr, 2002) . The functional relevance of the BC-box in TMF/ARA160 was corroborated by the compromised function of the HA-ATMF (S 333 LD-AAA) mutant. In this mutant, two (Ser 333 and Leu
334
) out of the four conserved residues in the BC-box consensus sequence were replaced with Ala residues. The decreased ubiquitination-directing activity of HA-ATMF therefore supports our conclusion that TMF/ ARA160 harbors a functional BC-box element.
Similar to VHL and F-box proteins (DeSalle and Pagano, 2001), TMF/ARA160 may serve as an adaptor to recruit a defined protein -Stat3, to ubiquitination by an E3 ubiquitin ligase complex. This may then lead to the subsequent proteasomal degradation of Stat3 (Kamura et al., 2002) . It should be stressed that sequence analysis did not reveal F-box motifs (Craig and Tyers, 1999; Jackson and Eldridge, 2002) in TMF/ ARA160, supporting the notion that TMF/ARA160 could associate with an E3 ligase through its BC-box element . The binding of TMF/ ARA160 to its target protein -Stat3, could be mediated by cc forming sequences which are located in the central and C-terminal parts of the molecule (Garcia et al., 1992;  Figure 5a ). Indeed, deletion of the C-terminal cc domain abolished the ability of TMF/ARA160 to direct the degradation of Stat3 (Figure 7) . A similar presence of cc domains was found in another BC-box-containing protein -Muf1, which can associate with E3 complexes and like TMF/ARA160 bears a BC-box in its Nterminal end, and leucine-rich stretches in its C-terminal part (Kamura et al., 2001) .
The TMF/ARA160-mediated degradation of Stat3 might be enhanced by the dispersion of the Golgi apparatus in the serum-starved C2C12 cells, since dispersion of the Golgi could increase the accessibility of TMF/ARA160 to Stat3. The Golgi is also undergoing disintegration and dispersion during mitosis of mammalian cells (Colanzi et al., 2003) . This could also allow the interaction of TMF/ARA160 and Stat3 at defined stages of the cell cycle, and would lead to the degradation of Stat3 under defined growth conditions. Hence, TMF/ARA160 could serve as a regulator of Stat3 and cell proliferation. This coincides with the reduced levels of TMF/ARA160 in aggressive malignant brain tumors (Figure 8 ). Further analysis should reveal whether TMF/ARA160 is downregulated in other tumors, an observation that will portray it as a novel tumor suppressor protein.
The confinement of TMF/ARA160 to the Golgi implies a novel role for that organelle in the modulation of cell growth. The Golgi, like the mitochondria (Scheffler, 2001) , seems to harbor a cellular regulator that antagonizes tumor progression and is activated and dispersed in the cytoplasm, under defined cellular conditions. Interestingly, disintegration of the Golgi by BFA in various cancer cells led to the degradation of key cell-cycle regulators and consequent cell death (Chapman et al., 1999) . Further studies should reveal whether TMF/ARA160 is involved in the activation of that cancer therapeutic approach, and in other growthcontrolling processes.
Materials and methods

Cell lines and tissue samples
C2C12 were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco Inc.) supplemented with 15% fetal calf serum (FCS) (Beit Haemek Inc.) and 4% glucose. For growth arrest, cells were transferred to medium containing either 0.1 or 0.5% FCS and 4% glucose. Cells treated with proteasome inhibitor were exposed for 5 h to 50 mM MG132, before being harvested.
Meningiomas were obtained from the Haddasa medical center, Jerusalem, Israel. They were cytologically characterized and described before (Weisberg et al., 2001) . Glioblastomas were characterized and obtained from the Rabin Medical Center, Petach-Tikva, Israel. Rat brain cerebral cortex cells were prepared by surgically removing the cortex from the brains of 3-days-old newborn rats.
Preparation of anti-TMF/ARA160 antibodies cDNA fragment encoding amino acids (aa) 0-268, of the human TMF/ARA160 (N-TMF/ARA160), was flanked by Sph1 and Xho1 sites, and was inserted between the Sph1 and Sal1 sites in the pQE32, bacterial expression vector (Qiagen Inc.) . In this vector, the expressed protein is preceded at its Nterminus by six histidine residues, and could thus be purified by immobilized metal affinity chromatography (IMAC). The TMF/ARA160 N-terminal fragment was expressed in Escherichia coli JM109 cells and was then purified by IMAC, using TALON-metal affinity resin (Clontech Inc.), which consists of Sepharose-cobalt beads. Purified TMF/ARA160 fragments (200 mg) were injected subcutaneously to 3-month-old female rabbits. This was repeated two more times with 14 days intervals, and the presence of anti-TMF/ARA160 antibodies in the obtained sera was determined using ELISA.
For immunocytochemical and immunoprecipitation analysis, TMF/ARA160 anti-sera were affinity purified on a CNBractivated Sepharose, to which the N-TMF/ARA160 antigen was covalently linked. The serum was passed through the column three times and nonrelevant proteins were washed TMF/ARA160 mediates degradation of Stat3 E Perry et al away with phosphate-buffered saline (PBS). Anti-TMF/ ARA160 antibodies were eluted with 100 mM glycine buffer (pH 2.5), followed by basic elution with 100 mM triethylamine (pH 11.5). Acidic fractions were neutralized with 1 M phosphate buffer (pH 8) and basic fractions were neutralized with 1 M phosphate buffer (pH 6.8). The titer and specificity of the aTMF/ARA160 antibodies in each fraction were determined using ELISA and Western blot analysis.
Immunocytochemical analysis
Immunocytochemistry was carried out essentially as described before (Ben-Dor et al., 1999; Priel-Halachmi et al., 2000) . For TMF/ARA160 staining, cells were exposed to 1 : 50 diluted, affinity-purified anti-TMF/ARA160 antibodies. Rabbit polyclonal antibodies were visualized with fluorescein isothiocyanate conjugated donkey anti-rabbit secondary antibodies (Jackson Laboratories). Nuclei were visualized by staining the DNA with 0.05 mg/ml propidium iodide, and the Golgi apparatus was stained with a fluorescein isothiocyanateconjugated WGA. Bound fluorophors were detected with a Bio-Rad MRC 1024 upright confocal microscope with a krypton-argon ion laser. Confocal microscope image analysis was performed using Bio-Rad software, and figures were compiled using the Laser Sharp 3.0 software package.
Western blot analysis
Whole-cell protein lysates were prepared and 25 mg of each sample was resolved by 7% SDS-PAGE, as described before . Electroblotted proteins were detected using polyclonal anti-TMF/ARA160 and anti-Fer antibodies, monoclonal anti-Stat3 and anti-Stat1 (Transduction Lab. Inc.), and monoclonal antiubiquitin antibodies (Cell-signaling Inc.). Whole-cell cerebral cortex lysates were prepared by mechanical homogenization of the tissue mass in lysis buffer . Homogenates were cleared by centrifugation and supernatants were collected for further analysis.
Immunoprecipitation
Immunoprecipitations were performed basically, as described before . In brief, extracted proteins (750-1000 mg) were incubated overnight at 41C with 1 : 50 affinity-purified anti-TMF/ARA160 polyclonal antibodies. Antigen-antibody complexes were precipitated with protein A-Sepharose for 1.5 h at 41C and were washed as described before . Precipitated proteins were then resolved by SDS-PAGE, blotted onto nitrocellulose membranes, and reacted with polyclonal anti-Fer, antiubiquitin and anti-TMF/ARA160 antibodies, or monoclonal anti-Stat1, anti-HA (Babco Inc.), anti-myc (Zymed Inc.) and anti-Stat3 antibodies.
Construction of plasmids
The construction of the pCDNA3-HATMF plasmid was described before (Schwartz et al., 1998) . The pCDNA3-HADBCTMF plasmid was constructed in two consecutive steps. Firstly, a fragment of the human TMF/ARA160 cDNA extending from 4 to 996 nt (18) was amplified with a forward primer -5 0 CGCGGATCCAGTTGGTTCAACGCCTCC-CAGCT 3 0 , which bared a BamHI site at its 5 0 end, and with a backward primer -5 0 ATAAGAATGCGGCCGCTGTA-CACTAAATGAGTCTATT 3 0 , which bared a NotI site at its 5 0 end. The amplified fragment was cloned into a pCDNA3HA vector digested with BamHI and NotI. The resulting plasmid was cut with NotI and ApaI, and was ligated with another TMF/ARA160 amplification product of nucleotides 1028-3282 (Garcia et al., 1992) , which was obtained with a forward primer -5 0 ATAAGAATGCGGCCGCATTCA-GATGATGAATTGTCAGG 3 0 baring a NotI site at its 5 0 , and a backward primer -5 0 GAATGGGCCCTTAACTGA-GACTTTGTCTTAAAAGT 3 0 baring an ApaI site at its 5 0 . In this construct, aa Ser-333-Gln-343 were removed from the TMF/ARA160 protein. The plasmid encoding TMF/ARA160 that harbors point mutations in the BC-box element -SLD (333-335)-AAA (HA-ATMF) -was constructed using the 'site-directed mutagenesis' method as follows: Primers A and B are reverse complement primers that contain the mutated residues: A -5 0 . The two overlapping cDNA portions were separately amplified and were then mixed, denatured and allowed to complete a mutated double-stranded fragment using a Pfu DNA polymerase. The obtained mutated fragment was then amplified and cloned into a corresponding TMF cDNA fragment.
The pCMVmyc-elonginC plasmid was constructed by amplifying a human elongin C cDNA clone with a forward primer -5 0 GAAGATCTTGGATGGAGAGGAGAAAACCT 3 0 , which bares at its 5 0 end a BglII site, and a backward primer -5 0 GGGGTACCTTAACAATCTAAGAAGTTCGC 3 0 , which bared a KpnI site at its 3 0 end. The amplified fragment was then cloned into a BglII-KpnI cut pCMV-myc vector (BD Clonetech Inc).
Transfection of cells
C2C12 cells were maintained in DMEM, supplemented with 15% fetal calf serum. Cells (2.5 Â 10 5 ) were seeded in 10 cm plates, 20 h before transfection. Cells were transiently transfected using the LipofectAMINE reagent, according to the manufacturer's instructions (Invitrogen). Each transfection was performed by mixing 15 mg DNA with 32 ml of LipofectA-MINE and 1.2 ml serum-free, Opti-MEM (Gibco) medium. The mixture was incubated for 25 min at room temperature, and was then diluted in 4.8 ml of serum-free medium. Diluted DNA suspensions were overlaid onto the cells which were then incubated for 6.5 h at 371C in a CO 2 incubator. After incubation, 12 ml Opti-MEM, supplemented with 15% FCS, was added, and these were replaced after 15 h with 10 ml fresh DMEM containing 15% FCS. When downregulation of Stat3 was studied, the added DMEM contained 0.1% FCS. Cells were fixed for immunocytochemical analysis or were harvested for protein extraction, 48 h after transfection.
In vivo ubiquitination assay 6 Â 10 5 C2C12 cells were co-transfected with 5 mg 6 Â His-Stat3 and 10 mg HA-TMF/ARA160 constructs. At 48 h after transfection, cells were lysed with 1 ml guanidinium-HCl buffer (6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 8.0)). Lysates were sonicated with a SONICATOR 3000 microtip (MISONIX) at 1.5 W for four cycles of 5 s each, to reduce viscosity, and were then mixed with 0.1 ml of metal (Co 2 þ )-affinity Resin (Clontech) for 4 h at room temperature, in a vertically rotating 2 ml tube (Treier et al., 1994) . The mix was successively washed with the following solutions: 1 ml guanidinium-HCl; 2 ml of 6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 5.8); 1 ml guanidinium-HCl; 2 ml of guanidinium-HCl : protein buffer (50 mM Na 2 HPO 4 / NaH 2 PO 4 (pH 8.0), 100 mM KCl, 20% glycerol and 0.2% NP-40) 1 : 1; 2 ml of guanidinium-HCl : protein buffer 1 : 3; 2 ml of protein buffer; 1 ml of protein buffer. Elution was carried out with 30 ml Laemli buffer containing 10 mM EDTA. Eluted proteins were resolved in 7% SDS-PAGE for a Western blot analysis.
Abbreviations
Stat3, signal transducer and activator of transcription 3; HIV1, human immunodeficiency 1; LTR, long-terminal repeat; AR, androgen receptor; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; PBS, phosphate-buffered saline.
